Pfizer R&D to split into large and small molecule divisions

Share this article:

Pfizer announced organizational plans for the company post-Wyeth acquisition, including a new focus on biopharmaceuticals.

According to a statement today, Pfizer will retain eight senior executives from Wyeth, and form two separate research organizations. One will focus on the discovery of small molecules and will be headed by Martin Mackay, currently president of Pfizer's global R&D. The second group will focus on large-molecule research—including vaccines—and will be led by Mikael Dolsten, currently president of Wyeth research.

Within the two R&D groups, Pfizer will task several chief scientific officers with specific areas of responsibility, including vaccine research (Emilio Emini, Wyeth's vaccine R&D head) and neuroscience research (Menelas Pangalos, Wyeth's head of discovery).

“Creating two distinct, but complementary, research organizations, led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery,” said Jeff Kindler, Pfizer's CEO, in the statement.

Following the acquisition, Pfizer will organize itself into nine business areas:

• Primary care, led by Olivier Brandicourt (Pfizer)

• Specialty care and vaccines, led by Geno Germano (Wyeth)

• Emerging markets, led by Jean-Michel Halfon (Pfizer)

• Oncology, led by Garry Nicholson (Pfizer)

• Established products, led by David Simmons (Pfizer)

• Animal Health, led by Juan-Ramon Alaix (Pfizer)

• Capsugel, led by Guido Driesen (Pfizer)

• Consumer health, led by Paul Sturman (Wyeth)

• Nutritional health, led by Erica Mann (Wyeth) 

Pfizer and Wyeth expect the acquisition to be finalized “at the end of the third quarter, or during the fourth quarter of 2009,” according to the statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...